Roth Capital Analysts Give Teligent, Inc. (TLGT) a $9.00 Price Target
Other analysts have also recently issued reports about the company. Canaccord Genuity initiated coverage on Teligent in a research note on Monday, July 31st. They issued a buy rating and a $11.00 price target on the stock. Deutsche Bank AG cut their price target on Teligent from $9.00 to $8.00 and set a hold rating on the stock in a research note on Monday, August 14th. ValuEngine cut Teligent from a hold rating to a sell rating in a research note on Tuesday, July 25th. BidaskClub cut Teligent from a hold rating to a sell rating in a research note on Monday, July 24th. Finally, Zacks Investment Research cut Teligent from a hold rating to a sell rating in a research note on Thursday, July 6th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of $9.00.
Shares of Teligent (NASDAQ TLGT) opened at 6.48 on Wednesday. The stock’s market capitalization is $345.97 million. Teligent has a 1-year low of $5.75 and a 1-year high of $9.54. The stock has a 50 day moving average price of $7.53 and a 200-day moving average price of $7.95.
Teligent (NASDAQ:TLGT) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.02 by $0.04. Teligent had a negative net margin of 11.36% and a positive return on equity of 1.49%. The business had revenue of $18.40 million during the quarter, compared to analyst estimates of $20.11 million. During the same quarter in the prior year, the business earned $0.02 earnings per share. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. On average, analysts forecast that Teligent will post $0.07 earnings per share for the current year.
Several hedge funds have recently bought and sold shares of TLGT. Parkwood LLC purchased a new stake in Teligent during the second quarter worth approximately $112,000. Teza Capital Management LLC purchased a new stake in Teligent during the first quarter worth approximately $116,000. UBS Asset Management Americas Inc. purchased a new stake in Teligent during the first quarter worth approximately $170,000. Renaissance Technologies LLC purchased a new stake in Teligent during the first quarter worth approximately $198,000. Finally, American International Group Inc. boosted its stake in Teligent by 7.1% in the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock worth $199,000 after buying an additional 1,680 shares during the period. Institutional investors and hedge funds own 62.88% of the company’s stock.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Stock Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related stocks with our FREE daily email newsletter.